statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Piper Sandler Remains a Buy on Nurix Therapeutics (NRIX)

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Nurix Therapeutics (NRIX Research Report) today and set a price target of $35.0...

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike

Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike Biotech Advances Propel Oncology Market to $564.5B Amid Youth Cancer Spike PR Newswire VANCOUVER, BC, June 20, 2024 USA News...

What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-5948 showed promising safety and efficacy in Phase 1a/b trials for...

Why Nurix Therapeutics Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

Key Takeaways From Nurix Therapeutics Analyst Ratings

Latest Ratings for NRIX
 DateFirmActionFromTo Feb 2022Wells FargoInitiates Coverage OnEqual-Weight Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Oct 2021SVB LeerinkMaintainsOutperform...

Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling over 50 points on Friday.
read more...

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates Nurix will receive a $15.0 million extension fee, and will remain eligible for...

Commit To Purchase Nurix Therapeutics At $10, Earn 18.3% Annualized Using Options

Investors considering a purchase of Nurix Therapeutics Inc (NRIX) stock, but cautious about paying the going market price of 15.09/share, might benefit from considering selling puts among the...

Nurix Therapeutics part of team selected as Cancer Grand Challenges awardees

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Volume	590,612.00
52-Wk High	$24.38
52-Wk Low	$4.22

NRIX Nurix Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals